|
|
 Previous Article | Table of Contents | Next Article 
Genetic Polymorphism in MDR-1: A Tool for Examining
Allelic Expression in Normal Cells, Unselected and Drug-Selected
Cell Lines, and Human Tumors
Lyn A. Mickley,
Jong-Seok Lee,
Zheng Weng,
Zhirong Zhan,
Manuel Alvarez,
Wyndham Wilson,
Susan E. Bates, and
Tito Fojo
From the Medicine Branch, Division of Clinical Sciences
(DCS), National Cancer Institute (NCI), Bethesda, MD; and
the Department of Internal Medicine, Gyeongsang National University,
Chinju, Kyungnam, South Korea.
By using RNase protection analysis, residues 2677 and 2995 of
MDR-1 were identified as sites of genetic polymorphism. Through use of oligonucleotide hybridization, the genomic content and expression of individual MDR-1 alleles were examined in normal tissues, unselected and drug selected cell lines, and malignant lymphomas. In normal tissues, unselected cell lines, and untreated malignant lymphoma samples, expression of MDR-1 from both
alleles was similar. In contrast, in drug selected cell lines, and in relapsed malignant lymphoma samples, expression of one allele was found
in a large percentage of samples. To understand how expression of one
allele occurs, two multidrug resistant sublines were isolated by
exposing a Burkitt lymphoma cell line to increasing concentrations of
vincristine. The resistant sublines expressed only one allele and had a
hybrid MDR-1 gene composed of non-MDR-1 sequences
proximal to MDR-1. Previous studies showing hybrid
MDR-1 genes after rearrangements provided a potential
explanation for activation and expression of one MDR-1 allele.
We conclude that oligonucleotide hybridization can be used as a
sensitive tool to examine relative allelic expression of MDR-1,
and can identify abnormal expression from a single allele. Acquired
drug resistance in vitro and in patients is often associated with
expression of a single MDR-1 allele, and this can be a marker
of a hybrid MDR-1 gene.
Blood, Vol. 91 No. 5 (March 1), 1998:
pp. 1749-1756
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Pajic, J. K. Iyer, A. Kersbergen, E. van der Burg, A. O.H. Nygren, J. Jonkers, P. Borst, and S. Rottenberg
Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer
Cancer Res.,
August 15, 2009;
69(16):
6396 - 6404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Streetman
Clinical Pharmacogenetics of the Major Adenosine Triphosphate Binding Cassette and Solute Carrier Drug Transporters
Journal of Pharmacy Practice,
June 1, 2007;
20(3):
219 - 233.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. M. Huff, J.-S. Lee, R. W. Robey, and T. Fojo
Characterization of Gene Rearrangements Leading to Activation of MDR-1
J. Biol. Chem.,
December 1, 2006;
281(48):
36501 - 36509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mickley Huff, Z. Wang, A. Iglesias, T. Fojo, and J.-S. Lee
Aberrant Transcription from an Unrelated Promoter Can Result in MDR-1 Expression following Drug Selection In vitro and in Relapsed Lymphoma Samples
Cancer Res.,
December 15, 2005;
65(24):
11694 - 11703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Chen, Y. C. Wang, M. E. Schaner, B. Francisco, G. E. Duran, D. Juric, L. M. Huff, H. Padilla-Nash, T. Ried, T. Fojo, et al.
Genetic and Epigenetic Modeling of the Origins of Multidrug-Resistant Cells in a Human Sarcoma Cell Line
Cancer Res.,
October 15, 2005;
65(20):
9388 - 9397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Putnam, J. M. Woo, Y. Huang, and L. Z. Benet
Effect of the MDR1 C3435T Variant and P-Glycoprotein Induction on Dicloxacillin Pharmacokinetics
J. Clin. Pharmacol.,
April 1, 2005;
45(4):
411 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Geromin, J.-F. Bourge, A. Soulie, R. Pawliuk, C. Fleet, E. Michel, Y. Denizot, C. Berthou, P. Leboulch, F. Sigaux, et al.
Glycoprotein 170 Induces Platelet-Activating Factor Receptor Membrane Expression and Confers Tumor Cell Hypersensitivity to NK-Dependent Cell Lysis
J. Immunol.,
March 15, 2004;
172(6):
3604 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Lockhart, R. G. Tirona, and R. B. Kim
Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy
Mol. Cancer Ther.,
July 1, 2003;
2(7):
685 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Illmer, U. S. Schuler, C. Thiede, U. I. Schwarz, R. B. Kim, S. Gotthard, D. Freund, U. Schakel, G. Ehninger, and M. Schaich
MDR1 Gene Polymorphisms Affect Therapy Outcome in Acute Myeloid Leukemia Patients
Cancer Res.,
September 1, 2002;
62(17):
4955 - 4962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kimchi-Sarfaty, J. J. Gribar, and M. M. Gottesman
Functional Characterization of Coding Polymorphisms in the Human MDR1 Gene Using a Vaccinia Virus Expression System
Mol. Pharmacol.,
July 1, 2002;
62(1):
1 - 6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U Potocnik, M Ravnik-Glavac, R Golouh, and D Glavac
Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers
J. Med. Genet.,
May 1, 2002;
39(5):
340 - 346.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.-j. Wang, C. N. Casciano, R. P. Clement, and W. W. Johnson
Evaluation of the Interaction of Loratadine and desloratadine with P-glycoprotein
Drug Metab. Dispos.,
August 1, 2001;
29(8):
1080 - 1083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, Y. Kanamori, M. Takahashi, Y. Kurata, J. Kigawa, S. Higuchi, et al.
Expression of P-glycoprotein in Human Placenta: Relation to Genetic Polymorphism of the Multidrug Resistance (MDR)-1 Gene
J. Pharmacol. Exp. Ther.,
June 1, 2001;
297(3):
1137 - 1143.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. M. van den Heuvel-Eibrink, E. A. C. Wiemer, M. J. de Boevere, B. van der Holt, P. J. M. Vossebeld, R. Pieters, and P. Sonneveld
MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3605 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Verdier-Pinard, J. A. Kepler, G. R. Pettit, and E. Hamel
Sustained Intracellular Retention of Dolastatin 10 Causes Its Potent Antimitotic Activity
Mol. Pharmacol.,
January 1, 2000;
57(1):
180 - 187.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. E. Bates
Drug Resistance: Still on the Learning Curve
Clin. Cancer Res.,
November 1, 1999;
5(11):
3346 - 3348.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. E. Evans and M. V. Relling
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Science,
October 15, 1999;
286(5439):
487 - 491.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Hoffmeyer, O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, et al.
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
PNAS,
March 28, 2000;
97(7):
3473 - 3478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
